<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The therapeutic effect of Glatiramer <z:chebi fb="49" ids="30089,47622">acetate</z:chebi>, an immune modulating agent, was evaluated in the dy(2J)/dy(2J) mouse with merosin deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, which is a milder variant of the dy/dy mouse </plain></SENT>
<SENT sid="1" pm="."><plain>The treated mice showed significant improvement in hind limb muscle strength measured by electronic grip strength meter and in motor performance quantified by video detection software </plain></SENT>
<SENT sid="2" pm="."><plain>Glatiramer <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> treatment was associated with significantly increased expression of regeneration transcription factors MyoD and myogenin, and attenuation of the <z:mp ids='MP_0003045'>fibrosis</z:mp> markers vimentin and fibronectin </plain></SENT>
<SENT sid="3" pm="."><plain>No effective treatment is currently available in <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> and Glatiramer <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> may present a new potential treatment for this disorder </plain></SENT>
</text></document>